Cancers (May 2022)
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
- Jorge Labrador,
- David Martínez-Cuadrón,
- Adolfo de la Fuente,
- Rebeca Rodríguez-Veiga,
- Josefina Serrano,
- Mar Tormo,
- Eduardo Rodriguez-Arboli,
- Fernando Ramos,
- Teresa Bernal,
- María López-Pavía,
- Fernanda Trigo,
- María Pilar Martínez-Sánchez,
- Juan-Ignacio Rodríguez-Gutiérrez,
- Carlos Rodríguez-Medina,
- Cristina Gil,
- Daniel García Belmonte,
- Susana Vives,
- María-Ángeles Foncillas,
- Manuel Pérez-Encinas,
- Andrés Novo,
- Isabel Recio,
- Gabriela Rodríguez-Macías,
- Juan Miguel Bergua,
- Víctor Noriega,
- Esperanza Lavilla,
- Alicia Roldán-Pérez,
- Miguel A. Sanz,
- Pau Montesinos,
- on behalf of PETHEMA Group
Affiliations
- Jorge Labrador
- Hematology Department, Research Unit, Complejo Asistencial Universitario de Burgos, 09006 Burgos, Spain
- David Martínez-Cuadrón
- Hematology Department, Hospital Universitari i Politécnic La Fe, 46026 Valencia, Spain
- Adolfo de la Fuente
- Hematology Department, MD Anderson Cancer Center Madrid, 28033 Madrid, Spain
- Rebeca Rodríguez-Veiga
- Hematology Department, Hospital Universitari i Politécnic La Fe, 46026 Valencia, Spain
- Josefina Serrano
- Hematology Department, Hospital Universitario Reina Sofía, IMIBIC, 14004 Córdoba, Spain
- Mar Tormo
- Hematology Department, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria—INCLIVA, 46010 Valencia, Spain
- Eduardo Rodriguez-Arboli
- Hematology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), 41013 Sevilla, Spain
- Fernando Ramos
- Hematology Department, Hospital Universitario de León, 24071 León, Spain
- Teresa Bernal
- Hematology Department, Hospital Universitario Central Asturias, ISPA, IUOPA, 33011 Oviedo, Spain
- María López-Pavía
- Hematology Department, Hospital General de Valencia, 46026 Valencia, Spain
- Fernanda Trigo
- Hematology Department, Centro Hospitalar Universitário de São João, 4200-319 Porto, Portugal
- María Pilar Martínez-Sánchez
- Hematology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- Juan-Ignacio Rodríguez-Gutiérrez
- Hematology Department, Hospital Universitario Basurto, 48013 Bilbao, Spain
- Carlos Rodríguez-Medina
- Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, 35010 Las Palmas de Gran Canaria, Spain
- Cristina Gil
- Hematology Department, Hospital General Universitario de Alicante, 03010 Alicante, Spain
- Daniel García Belmonte
- Hematology Department, Hospital Universitario Sanitas La Zarzuela, 28023 Madrid, Spain
- Susana Vives
- Hematology Department, Hospital Germans Trias i Pujol-ICO, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, 08916 Badalona, Spain
- María-Ángeles Foncillas
- Hematology Department, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain
- Manuel Pérez-Encinas
- Hematology Department, Hospital Clínico Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain
- Andrés Novo
- Hematology Department, Hospital Universitario Son Espases, 07120 Palma de Mallorca, Spain
- Isabel Recio
- Hematology Department, Complejo Asistencial de Ávila, 05071 Avila, Spain
- Gabriela Rodríguez-Macías
- Hematology Department, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
- Juan Miguel Bergua
- Hematology Department, Hospital San Pedro de Alcántara, 10003 Caceres, Spain
- Víctor Noriega
- Hematology Department, Hospital Universitario de A Coruña, 15006 La Coruna, Spain
- Esperanza Lavilla
- Hematology Department, Hospital Universitario Lucus Augusti, 27003 Lugo, Spain
- Alicia Roldán-Pérez
- Hematology Department, Hospital Universitario Infanta Sofía, 28702 San Sebastián de los Reyes, Spain
- Miguel A. Sanz
- Hematology Department, Hospital Universitari i Politécnic La Fe, 46026 Valencia, Spain
- Pau Montesinos
- Hematology Department, Hospital Universitari i Politécnic La Fe, 46026 Valencia, Spain
- on behalf of PETHEMA Group
- DOI
- https://doi.org/10.3390/cancers14092342
- Journal volume & issue
-
Vol. 14,
no. 9
p. 2342
Abstract
The hypomethylating agents, decitabine (DEC) and azacitidine (AZA), allowed more elderly acute myeloid leukemia (AML) patients to be treated. However, there are little direct comparative data on AZA and DEC. This multicenter retrospective study compared the outcomes of AZA and DEC in terms of response and overall survival (OS). Potential predictors associated with response and OS were also evaluated. A total of 626 AML patients were included (487 treated with AZA and 139 with DEC). Response rates were similar in both groups: CR was 18% with AZA vs. 23% with DEC (p = 0.20), CR/CRi was 20.5% vs. 25% (p = 0.27) and ORR was 32% vs. 39.5% (p = 0.12), respectively. Patients with leukocytes 9/L, bone marrow blasts p = 0.455), for AZA and DEC, respectively. Age (≥80 years), leukocytes (≥ 10 × 109/L), platelet count (9/L) and eGFR (≥45 mL/min/1.73 m2) were associated with higher OS with AZA compared to DEC. In conclusion, we found no differences in response and OS rates in AML patients treated with AZA or DEC.
Keywords
